Companies: 10,795·Total market cap: $144.5T
Apollomics, Inc.

Apollomics, Inc.

APLMNASDAQHealthcare● Active
$13.84
$-0.16(-1.14%)
Market Cap$15270336
P/E Ratio
52W High$42.12
52W Low$3.659

Apollomics, Inc. (APLM) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

aplm · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Apollomics, Inc. (APLM) measures how much investors pay for each dollar of the company's trailing earnings. APLM's current PE ratio of N/A is calculated by dividing its stock price of $13.84 by its TTM earnings per share of -$25.98.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-122.00
Based on 1 analyst
EPS (TTM)
-$25.98
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Apollomics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Apollomics, Inc.
Apollomics, Inc.You
APLM
$15MN/A-$25.98
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
ADAP
$75MN/A-$0.28
Adlai Nortye Ltd.
Adlai Nortye Ltd.
ANL
$530MN/A-$3.33
Athira Pharma, Inc.
Athira Pharma, Inc.
ATHA
$27MN/A-$24.70
BioLineRx Ltd.
BioLineRx Ltd.
BLRX
$14MN/A-$0.29
GeoVax Labs, Inc.
GeoVax Labs, Inc.
GOVX
$2MN/A-$22.40
SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation
ICU
$8MN/A-$0.59

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-7.57
2024-12-31
FY2024
$-58.13
2023-12-31
FY2023
$-232.00
2022-12-31
FY2022
$-277.45
2021-12-31
FY2021
$-109.22
2020-12-31
FY2020
$-86.20
2019-12-31
FY2019
$-52.89

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Apollomics, Inc. (APLM) measures how much investors pay for each dollar of the company's trailing earnings. APLM's current PE ratio of N/A is calculated by dividing its stock price of $13.84 by its TTM earnings per share of -$25.98.

PE Ratio = Stock Price ÷ EPS (TTM)
= $13.84 ÷ -$25.98 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

APLM pe ratio · 6 questions

APLM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $13.84 and TTM EPS of -$25.98. Data sourced from Financial Modeling Prep via APLM's SEC 10-K and 10-Q filings.

APLM PE ratioWhat is APLM PE ratioCurrent PE ratio of APLMAPLM PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Apollomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08